NCT07795814: A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
- State
- Under way
- Phase
- Phase 2
- People
- 90 planned
- Started
- 25 Aug 2026
- Primary completion
- Dec 2027
- Arms
- EDG-15400 50 mg
- Results
- None posted
- 25 Aug 2026: Trial started
- 31 Aug 2026: Trial registered